883977-08-0

Basic information

• Product Name: 3-(2-dimethylaminoethyl)phenylamine
• Synonyms: 3-(2-dimethylaminoethyl)phenylamine
• CAS NO: 883977-08-0
• Molecular Weight: 164.25
• Mol File: 883977-08-0.mol

Chemical Properties

• CAS DataBase Reference: 3-(2-dimethylaminoethyl)phenylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-dimethylaminoethyl)phenylamine(883977-08-0)
• EPA Substance Registry System: 3-(2-dimethylaminoethyl)phenylamine(883977-08-0)

Safety Data

• Hazardous Substances Data: 883977-08-0(Hazardous Substances Data)

Upstream product

• 16799-04-5 3-(2-Bromoethyl)nitrobenzene 
• 58730-43-1 2-(3-amino-phenyl)-N,N-dimethylacetamide 
• 126062-76-8 dimethyl-(3-nitro-phenethyl)-amine 

Downstream Products

• 1257078-19-5 4-(2-chloroimidazo[1,2-a]pyridin-3-yl)-N-(3-(2-(dimethylamino)ethyl)phenyl)pyrimidin-2-amine 
• 1245500-42-8 C₂₅H₂₃N₇O₂S 

Relevant articles and documents

IMIDAZO-CONDENSED BICYCLES AS INHIBITORS OF DISCOIDIN DOMAIN RECEPTORS (DDRS)

The invention provides a compound of formula (I) (Formula (I)) or a tautomeric form, stereochemically isomeric form, N-oxide, pharmaceutically acceptable salt or solvate thereof, wherein R2, R3, R4, Ra, Rb

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, L1, R2, R3, n, p, Ar1, and Ar2 are defined in the description. Methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.

PYRIMIDINE INHIBITORS OF KINASE ACTIVITY

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.